JP2022525013A - Hiv療法において有用な化合物 - Google Patents

Hiv療法において有用な化合物 Download PDF

Info

Publication number
JP2022525013A
JP2022525013A JP2021552772A JP2021552772A JP2022525013A JP 2022525013 A JP2022525013 A JP 2022525013A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2021552772 A JP2021552772 A JP 2021552772A JP 2022525013 A JP2022525013 A JP 2022525013A
Authority
JP
Japan
Prior art keywords
mmol
acid
fluoro
alkyl
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021552772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525013A5 (cg-RX-API-DMAC7.html
Inventor
マルタ、アリシア、デ、ラ、ローザ
ジョン、エフ.ミラー
デイビッド、テメルコフ
エミール、ジョハン、ベルジュイセン
ビー.ナラシムフル、ナイドゥ
ビセンテ、サマノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022525013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd, ViiV Healthcare Co filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2022525013A publication Critical patent/JP2022525013A/ja
Publication of JP2022525013A5 publication Critical patent/JP2022525013A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021552772A 2019-03-06 2020-03-04 Hiv療法において有用な化合物 Ceased JP2022525013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (2)

Publication Number Publication Date
JP2022525013A true JP2022525013A (ja) 2022-05-11
JP2022525013A5 JP2022525013A5 (cg-RX-API-DMAC7.html) 2024-07-16

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552772A Ceased JP2022525013A (ja) 2019-03-06 2020-03-04 Hiv療法において有用な化合物

Country Status (22)

Country Link
US (4) US12240853B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934760A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525013A (cg-RX-API-DMAC7.html)
KR (1) KR20210136052A (cg-RX-API-DMAC7.html)
CN (1) CN113811360A (cg-RX-API-DMAC7.html)
AR (1) AR118240A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020231934B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017604A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132112A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012579A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210460A (cg-RX-API-DMAC7.html)
EA (1) EA202192433A1 (cg-RX-API-DMAC7.html)
IL (1) IL285894A (cg-RX-API-DMAC7.html)
MA (1) MA55200A (cg-RX-API-DMAC7.html)
MX (1) MX2021010700A (cg-RX-API-DMAC7.html)
PE (1) PE20212089A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500034A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109253SA (cg-RX-API-DMAC7.html)
TW (1) TW202102233A (cg-RX-API-DMAC7.html)
WO (1) WO2020178767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106096B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541667A (ja) * 2019-07-27 2022-09-26 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
JP2025541056A (ja) * 2023-01-30 2025-12-18 メルク・シャープ・アンド・ドーム・エルエルシー 4’-置換ヌクレオシド逆転写酵素阻害剤のプロドラッグ

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
AU2022211056A1 (en) * 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090349A1 (ja) * 2004-03-24 2005-09-29 Yamasa Corporation 4’−c−置換−2−ハロアデノシン誘導体
JP2018532726A (ja) * 2015-09-23 2018-11-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv療法に有用な化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
UY34372A (es) 2011-10-06 2013-05-31 Dow Agrosciences Llc Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
SI2827875T1 (sl) 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CN107074899A (zh) * 2014-10-31 2017-08-18 桑多斯股份公司 改进的氟化工艺
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
WO2018085307A1 (en) 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
US12018435B2 (en) 2019-03-06 2024-06-25 Chemstone, Inc. Liquid dispersions for acyl halides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090349A1 (ja) * 2004-03-24 2005-09-29 Yamasa Corporation 4’−c−置換−2−ハロアデノシン誘導体
JP2018532726A (ja) * 2015-09-23 2018-11-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv療法に有用な化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NTIVIRAL CHEMISTRY & CHEMOTHERAPY, vol. 9, JPN6024013317, 1998, pages 311 - 323, ISSN: 0005437055 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022541667A (ja) * 2019-07-27 2022-09-26 ブリー バイオサイエンシーズ, インコーポレイテッド アデノシン誘導体及びそれを含む薬学的組成物
JP2023518433A (ja) * 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
JP2025541056A (ja) * 2023-01-30 2025-12-18 メルク・シャープ・アンド・ドーム・エルエルシー 4’-置換ヌクレオシド逆転写酵素阻害剤のプロドラッグ
JP7888031B2 (ja) 2023-01-30 2026-07-10 メルク・シャープ・アンド・ドーム・エルエルシー 4’-置換ヌクレオシド逆転写酵素阻害剤のプロドラッグ

Also Published As

Publication number Publication date
PE20212089A1 (es) 2021-11-04
US20260035371A1 (en) 2026-02-05
TW202102233A (zh) 2021-01-16
CO2021012579A2 (es) 2021-10-20
BR112021017604A2 (pt) 2021-11-16
EP3934760A1 (en) 2022-01-12
ZA202106096B (en) 2023-03-29
US12240853B2 (en) 2025-03-04
EA202192433A1 (ru) 2021-12-28
US20230174534A1 (en) 2023-06-08
US20220411425A1 (en) 2022-12-29
CR20210460A (es) 2022-02-03
WO2020178767A1 (en) 2020-09-10
AU2020231934B2 (en) 2023-04-20
MX2021010700A (es) 2021-10-01
CA3132112A1 (en) 2020-09-10
PH12021500034A1 (en) 2022-06-06
KR20210136052A (ko) 2021-11-16
SG11202109253SA (en) 2021-09-29
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
IL285894A (en) 2021-10-31
AR118240A1 (es) 2021-09-22
US20240182473A1 (en) 2024-06-06
MA55200A (fr) 2022-01-12
CL2021002309A1 (es) 2022-09-20
CN113811360A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
US20260035371A1 (en) Compounds useful in hiv therapy
TWI583696B (zh) 樺腦(betulin)衍生物
US8802727B2 (en) Pharmaceutically acceptable salts of betulinic acid derivatives
JP2021534112A (ja) Hiv療法に有用な化合物
US20210323993A1 (en) Compounds Useful in HIV Therapy
EP4021916A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
JP2021515771A (ja) Hiv療法に有用な化合物
US20140221328A1 (en) Pharmaceutically acceptable salts of novel betulinic acid derivatives
KR20140101869A (ko) 베툴린의 프로페노에이트 유도체
US20230151049A1 (en) Compounds Useful in HIV Therapy
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
JP2022543319A (ja) Hiv治療に有用な化合物
TW202245805A (zh) 腺苷衍生物及包含其之醫藥組合物
KR20180028535A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240405

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241011

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250221